Daniel R. Touchette

2.5k total citations
94 papers, 1.8k citations indexed

About

Daniel R. Touchette is a scholar working on Geriatrics and Gerontology, Economics and Econometrics and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Daniel R. Touchette has authored 94 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Geriatrics and Gerontology, 28 papers in Economics and Econometrics and 18 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Daniel R. Touchette's work include Pharmaceutical Practices and Patient Outcomes (30 papers), Health Systems, Economic Evaluations, Quality of Life (21 papers) and Medication Adherence and Compliance (16 papers). Daniel R. Touchette is often cited by papers focused on Pharmaceutical Practices and Patient Outcomes (30 papers), Health Systems, Economic Evaluations, Quality of Life (21 papers) and Medication Adherence and Compliance (16 papers). Daniel R. Touchette collaborates with scholars based in United States, United Kingdom and Tonga. Daniel R. Touchette's co-authors include Joseph Siemienczuk, Jacquelyn Hunt, Jessica Tilton, Alexandra Pérez, Daniel M. Hartung, James M. Hoffman, Fred Doloresco, Michelle T. Martin, Jacqueline S. Marinac and Glen T. Schumock and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of the American College of Cardiology and Neurology.

In The Last Decade

Daniel R. Touchette

87 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel R. Touchette United States 24 785 422 361 332 331 94 1.8k
Jennifer Martin United States 20 774 1.0× 274 0.6× 303 0.8× 293 0.9× 293 0.9× 49 1.8k
Sarah J. Billups United States 18 639 0.8× 335 0.8× 340 0.9× 249 0.8× 225 0.7× 63 1.1k
Lisa McCarthy Canada 25 884 1.1× 414 1.0× 190 0.5× 148 0.4× 434 1.3× 114 1.7k
Jo‐anne E Brien Australia 23 1.0k 1.3× 394 0.9× 442 1.2× 197 0.6× 388 1.2× 97 2.0k
Tobias Dreischulte Germany 20 943 1.2× 620 1.5× 224 0.6× 336 1.0× 592 1.8× 76 2.2k
Ronald L. Castelino Australia 23 884 1.1× 444 1.1× 457 1.3× 286 0.9× 258 0.8× 103 1.7k
Veerle Foulon Belgium 30 715 0.9× 301 0.7× 266 0.7× 525 1.6× 375 1.1× 166 3.1k
Lyne Lalonde Canada 27 675 0.9× 498 1.2× 566 1.6× 580 1.7× 473 1.4× 69 2.0k
Andreas Sönnichsen Germany 29 825 1.1× 555 1.3× 304 0.8× 635 1.9× 676 2.0× 108 2.8k
Benoît Allenet France 26 1.2k 1.5× 282 0.7× 453 1.3× 290 0.9× 270 0.8× 119 2.1k

Countries citing papers authored by Daniel R. Touchette

Since Specialization
Citations

This map shows the geographic impact of Daniel R. Touchette's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel R. Touchette with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel R. Touchette more than expected).

Fields of papers citing papers by Daniel R. Touchette

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel R. Touchette. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel R. Touchette. The network helps show where Daniel R. Touchette may publish in the future.

Co-authorship network of co-authors of Daniel R. Touchette

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel R. Touchette. A scholar is included among the top collaborators of Daniel R. Touchette based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel R. Touchette. Daniel R. Touchette is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Touchette, Daniel R., et al.. (2025). A systematic review of economic evaluations of clinical pharmacy Services in the United States: 2018–2022. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 8(5). 385–397.
2.
Norton, Rachel, et al.. (2024). Cost-effectiveness of a pharmacist-led medication therapy management clinic for management of type 2 diabetes. Journal of the American Pharmacists Association. 65(1). 102253–102253.
3.
Tice, Jeffrey A., et al.. (2024). Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti–acetylcholine receptor antibody–positive generalized myasthenia gravis. Journal of Managed Care & Specialty Pharmacy. 30(6). 517–527. 5 indexed citations
4.
Choi, Sun Ah, et al.. (2023). Cost-effectiveness of full and partial opioid agonists for opioid use disorder in outpatient settings: United States healthcare sector perspective. Journal of Substance Use and Addiction Treatment. 160. 209237–209237. 6 indexed citations
5.
6.
Touchette, Daniel R., et al.. (2023). Research and scholarly methods: Measuring medication adherence. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 6(4). 416–426. 26 indexed citations
7.
Shah, Kuldeep, et al.. (2023). EE8 Cost-Effectiveness of Long-Term Medication Therapy for Obesity Management. Value in Health. 26(6). S61–S61. 1 indexed citations
8.
Touchette, Daniel R. & Alexandra Pérez. (2023). Improving the quality of economic evaluations of clinical pharmacy services. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 6(6). 565–569. 1 indexed citations
9.
Agboola, Foluso, et al.. (2022). Cost-Effectiveness of Eculizumab and Efgartigimod for the Treatment of generalized Myasthenia Gravis (P1-1.Virtual). Neurology. 98(18_supplement). 3 indexed citations
10.
Tkacz, Joseph, et al.. (2022). PRIMUS – Prompt Initiation of Maintenance Therapy in the US: A Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Triple Therapy Following a COPD Exacerbation. Dove Medical Press (Taylor and Francis Group). 23 indexed citations
11.
Gerges, Michael, et al.. (2020). Work-Sampling Study of an Innovative Care Coordination Program Aimed at Children With Chronic Health Conditions. Professional Case Management. 25(6). 324–334. 1 indexed citations
12.
Touchette, Daniel R., Nicole Boyer, Steven J. Atlas, et al.. (2019). PMH16 LONG-TERM COST-EFFECTIVENESS OF ESKETAMINE FOR THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION. Value in Health. 22. S683–S683.
13.
Xing, Shan, et al.. (2018). Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States. Orphanet Journal of Rare Diseases. 13(1). 172–172. 10 indexed citations
14.
Kim, Kibum, Todd A. Lee, Daniel R. Touchette, et al.. (2016). Contemporary Trends in Oral Antiplatelet Agent Use in Patients Treated with Percutaneous Coronary Intervention for Acute Coronary Syndrome. Journal of Managed Care & Specialty Pharmacy. 23(1). 57–63. 30 indexed citations
15.
Kim, Kibum, Amer Ardati, Robert J. DiDomenico, Larisa H. Cavallari, & Daniel R. Touchette. (2014). COST-EFFECTIVENESS OF GENOTYPE/PHENOTYPE DRIVEN TICAGRELOR VERSUS CLOPIDOGREL SELECTION IN THE PATIENTS WITH ACUTE CORONARY SYNDROME. Journal of the American College of Cardiology. 63(12). A24–A24.
16.
Gerber, Ben S., Amparo Castillo, Jessica Tilton, et al.. (2012). Design of a trial to evaluate the impact of clinical pharmacists and community health promoters working with African-Americans and Latinos with Diabetes. BMC Public Health. 12(1). 891–891. 25 indexed citations
17.
18.
Martin, Michelle T., et al.. (2009). Medication Therapy Management Services. Drugs. 69(4). 393–406. 111 indexed citations
19.
Hunt, Jacquelyn, et al.. (2004). A first step towards translating evidence into practice: heartfailure in a community practice-based research network. Journal of Innovation in Health Informatics. 12(3). 139–145. 20 indexed citations
20.
Touchette, Daniel R., Tracy Durgin, Lee A. Wanke, & Donald E. Goodkin. (2003). A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-lb in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis. Clinical Therapeutics. 25(2). 611–634. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jennifer Martin Breakdown of academic impact, for papers by Sarah J. Billups Breakdown of academic impact, for papers by Lisa McCarthy Breakdown of academic impact, for papers by Jo‐anne E Brien Breakdown of academic impact, for papers by Tobias Dreischulte Breakdown of academic impact, for papers by Ronald L. Castelino Breakdown of academic impact, for papers by Veerle Foulon Breakdown of academic impact, for papers by Lyne Lalonde Breakdown of academic impact, for papers by Andreas Sönnichsen Breakdown of academic impact, for papers by Benoît Allenet
Rankless by CCL
2026